Amtagvi, a cellular therapy for solid tumors, has received FDA fast-track approval, offering hope for patients who have exhausted other treatment options for metastatic melanoma, a particularly deadly form of skin cancer.
Amtagvi, a cellular therapy for solid tumors, has received FDA fast-track approval, offering hope for patients who have exhausted other treatment options for metastatic melanoma, a particularly deadly form of skin cancer.
Be the first to know: Stories from The Washington Informer in your inbox each weekday.
We'll send a verification code to %EMAIL%.
Get the best of The Washington Informer directly in your email inbox.
Sending to: